Citigroup’s Soleno Therapeutics SLNO Stock Holding History

Citigroup’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-255,400	Closed	-$11.8M	–	6360
2025 Q4	$11.8M	Buy	255,400 +223,900	+711%	+$12.3M	0.01%	1410
2025 Q3	$2.13M	Buy	+31,500	New	+$2.34M	﹤0.01%	2623

Citigroup's SLNO Position: Q2 2026 in Review

Citigroup sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 56,656 shares — an estimated $1.9M sold.

Citigroup first reported a position in SLNO in Q1 2015 and held it in 20 quarters. The position peaked at $4.18M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Citigroup reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 56,656 Soleno Therapeutics shares in Q2 2026, an estimated $1.9M.
Citigroup first reported a position in Soleno Therapeutics in Q1 2015 and held it in 20 quarters.
Citigroup's Soleno Therapeutics position peaked at $4.18M in Q1 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.